Prevention Of Recurrence Of Atrial Fibrillation

A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study of the Safety and Efficacy of SB 207266 in Patients With Symptomatic Persistent Atrial Fibrillation (AF)

The purpose of this study is to determine whether the study drug is effective in preventing the recurrence of atrial fibrillation (an abnormal heart rhythm).

Inclusion Criteria:

• Symptomatic persistent atrial fibrillation requiring DC cardioversion.
• Duration of AF >48 hrs. <6 months

Exclusion Criteria:

• Concomitant Class I and/or III anti-arrhythmic drugs.
• Amiodarone treatment within 3 months of the study.
• Other inclusion or exclusion criteria to be determined by the physician and study sponsor.